India, March 18 -- In a regulatory filing made after market hours yesterday, the company informed that its step- down subsidiary, Strides Pharma International AG (SPIAG) has entered into definitive agreements with Sandoz AG, Switzerland, for the acquisition and in-licensing of a portfolio of branded generic products across Sub Saharan Africa (SSA).

The agreement spans four key markets, which include Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya.

The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti-infective, cardiovascular, and dermatology therapeutic segments.

Several of these products individually deliver annual sales exceeding $1 million, reflecting their establis...